{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nLncRNA PPP1R26‐AS1 is highly expressed in breast cancer tissues and cell lines, and its aberrant upregulation is strongly associated with adverse clinical parameters including advanced pTNM stage, positive estrogen receptor status, luminal B subtype, and nodal involvement. High expression of PPP1R26‐AS1 correlates with poorer overall survival, highlighting its potential role as an oncogenic factor and prognostic biomarker in breast cancer."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nMechanistically, PPP1R26‐AS1 functions as a competing endogenous RNA (ceRNA) by binding to miR-1226-3p, thereby modulating the expression of downstream targets that enhance cellular proliferation, invasion, and migration. Knockdown studies reveal that reducing PPP1R26‐AS1 levels results in significant decreases in these malignant behaviors, suggesting that this lncRNA is critical in promoting tumor aggressiveness and may offer a novel avenue for personalized therapeutic strategies in breast cancer."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Shuping Zhou, Shaoli Zhang, Hui Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Clinical Potential of lncRNA PPP1R26-AS1 in Breast Cancer and Its Contribution to Cancer Progression."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Biotechnol (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s12033-022-00452-w"}], "href": "https://doi.org/10.1007/s12033-022-00452-w"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35064892"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35064892"}]}]}]}